MR/PET in the Evaluation of Patients With Esophageal Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02547610

Enrollment

Registered

2015-09-11

Start date

2014-05-31

Completion date

2018-04-30

Last updated

2017-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Keywords

MR/PET in the evaluation, patients

Brief summary

In this prospective study, we will recruit newly diagnosed esophageal cancer patients and perform MR/PET before and after chemoradiation therapy. In MR, new image sequences will be added to the conventional sequences, such as high resolution image, DWI, DCE, cine imaging.

Detailed description

Total 80 patients will be recruited and followed after treatment complete for at least two years. We will compare the staging accuracy of MR/PET and PET/CT, and also analyze parameters that are predictive of disease recurrence and patient survival.

Interventions

DEVICEThe imaging biomarkers determined by MR-PET

Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 90 Years

Healthy volunteers

Inclusion criteria

1. newly diagnosed esophageal cancer patient 2. age older than 20 years

Exclusion criteria

1. For the safety reason, patients with the following conditions are contraindicated to enter magnetic resonance imaging (MRI) machine due to the high magnetic field, including: cardiac pacemaker, metallic artificial valve, intracranial and mediastinal vascular clips, cardiac defibrillator, nerve stimulator, implanted drug deliver system, metallic foreign body in the eye globe, cochlear implant, metallic fragments in the dangerous body part, Swan-Ganz catheter, and other metallic implants within 8 weeks: such as cardiac valve, stent, coil, filter, and clips. 2. patient who will receive endoscopic local therapy alone 3. unable to finish the standard surgical or radiation treatment 4. history of surgery or radiotherapy to the mediastinum 5. renal insufficiency, contraindication to MR imaging and contrast injection patient who have the severe allergic reaction the Gadollium contrast agent 6. patient who have the claustrophobic symptoms are also not suitable for this MR examination 7. pregnancy or lactating women

Design outcomes

Primary

Measure	Time frame
The imaging biomarkers determined by MR-PET	1 month

Countries

Taiwan

Contacts

Primary ContactTing-Fang Shih, MD

ttfshih@ntu.edu.tw+886-2-23123456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026